Advances in MRI assessment of gliomas and response to anti-VEGF therapy

Current Neurology and Neuroscience Reports

Volumn 11, Issue 3, 2011, Pages 336-344

  Pope, Whitney B ^a   Young, Jonathan R ^a   Ellingson, Benjamin M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis inhibitors; Bevacizumab; Glioblastoma; Gliomas; MR diffusion; MR perfusion; MR spectroscopy; Radiotracers

Indexed keywords

3' FLUOROTHYMIDINE F 18; 6 FLUORODOPA F 18; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CEDIRANIB; FERUMOXYTOL; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; METHIONINE C 11; TEMOZOLOMIDE; THALIDOMIDE; TRACER; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; TUMOR MARKER; VASCULOTROPIN A;

CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; DRUG RESPONSE; GLIOBLASTOMA; GLIOMA; HISTOGRAM; HUMAN; IMAGE ANALYSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; RADIATION RESPONSE; RECURRENT CANCER; REVIEW; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; TUMOR GROWTH; TUMOR NECROSIS; IMMUNOLOGY; METHODOLOGY; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79961132632     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-011-0179-x     Document Type: Review

References (47)

1. Norden AD, Drappatz J, Wen PY: Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. Dec 2008;7(12):1152-1160.
2. Wen PY, Macdonald DR, Reardon DA, et al.: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. Apr 10 2010;28 (11):1963-1972.
3. Rees JH, Smirniotopoulos JG, Jones RV, Wong K: Glioblastoma multiforme: radiologic-pathologic correlation. Radiographics. Nov 1996;16(6):1413-1438; quiz 1462-1413.
4. Clarke JL, Chang S: Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep. May 2009;9(3):241-246.
5. Brandsma D, van den Bent MJ: Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol. December 2009;22(6):633-638.
6. Kim JH, Chung YG, Kim CY, et al.: Upregulation of VEGF and FGF2 in normal rat brain after experimental intraoperative radiation therapy. J Korean Med Sci. Dec 2004;19(6):879-886. (Pubitemid 40104884)
7. Gonzalez J, Kumar AJ, Conrad CA, Levin VA: Effect of bevacizumab on radiation necrosis of the brain. Int J Radiat Oncol Biol Phys. Feb 1 2007;67(2):323-326. (Pubitemid 46108339)
8. Hirai T, Murakami R, Nakamura H, et al.: Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study. AJNR Am J Neuroradiol. Sep 2008;29(8):1505-1510.
9. Sawlani RN, Raizer J, Horowitz SW, et al.: Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging-pilot study. Radiology. May 2010;255(2):622-628.
10. Sorensen AG, Batchelor TT, Zhang WT, et al.: A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. Jul 1 2009;69(13):5296-5300.
11. Kamoun WS, Ley CD, Farrar CT, et al.: Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. May 20 2009;27(15):2542-2552.
12. Cha S, Knopp EA, Johnson G, et al.: Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol. May 2000;21(5):881-890. (Pubitemid 30262835)
13. Akella NS, Twieg DB, Mikkelsen T, et al.: Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial. J Magn Reson Imaging. Dec 2004;20(6):913-922. (Pubitemid 39577891)
14. Mangla R, Singh G, Ziegelitz D, et al.: Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology. Aug 2010;256(2):575-584.
15. Law M, Young RJ, Babb JS, et al.: Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology. May 2008;247(2):490-498.
16. Caseiras GB, Ciccarelli O, Altmann DR, et al.: Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient. Radiology. Nov 2009;253(2):505-512.
17. Cao Y, Tsien CI, Nagesh V, et al.: Survival prediction in highgrade gliomas by MRI perfusion before and during early stage of RT [corrected]. Int J Radiat Oncol Biol Phys. Mar 1 2006;64 (3):876-885. (Pubitemid 43183588)
18. Barajas RF, Jr., Chang JS, Segal MR, et al.: Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibilityweighted contrast-enhanced perfusion MR imaging. Radiology. Nov 2009;253(2):486-496.
19. Hu LS, Baxter LC, Smith KA, et al.: Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol. Mar 2009;30(3):552-558.
20. Sugahara T, Korogi Y, Tomiguchi S, et al.: Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrastenhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol. May 2000;21(5):901-909. (Pubitemid 30262837)
21. Lev MH, Ozsunar Y, Henson JW, et al.: Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol. Feb 2004;25(2):214-221. (Pubitemid 38235298)
22. Paulson ES, Schmainda KM: Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology. Nov 2008;249(2):601-613.
23. Gahramanov S, Raslan AM, Muldoon LL, et al.: Potential for Differentiation of Pseudoprogression from True Tumor Progression with Dynamic Susceptibility-weighted Contrast-enhanced Magnetic Resonance Imaging using Ferumoxytol vs. Gadoteridol: A Pilot Study. Int J Radiat Oncol Biol Phys. Apr 13 2010.
24. Moffat BA, Chenevert TL, Meyer CR, et al.: The functional diffusion map: An imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia. 2006;8(4):259-267.
25. Hamstra DA, Chenevert TL, Moffat BA, et al.: Evaluation of the functional diffusion map as an early biomarker of time-toprogression and overall survival in high-grade glioma. Proc Nat Acad Sci. 2005;102(46):16759-16764. (Pubitemid 41688850)
26. Hamstra DA, Galbán CJ, Meyer CR, et al.: Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol. 2008;26(10):3387-3394.
27. Ellingson BM, Malkin MG, Rand SD, et al.: Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31(3):538-548.
28. Ellingson BM, Malkin MG, Rand SD, et al.: Functional diffusion maps applied to FLAIR abnormal areas are valuable for the clinical monitoring of recurrent brain tumors. Proc Intl Soc Mag Reson Med. 2009;17:285.
29. Ellingson BM, Rand SD, Malkin MG, Schmainda KM: Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri. J Neurooncol. 2010;97(3):419-423.
30. Ellingson BM, Malkin MG, Rand SD, et al.: Comparison of cytotoxic and anti-angiogenic treatment responses using functional diffusion maps in FLAIR abnormal regions. Proc Intl Soc Mag Reson Med. 2009;17:1010.
31. Ellingson BM, Malkin MG, Rand SD, et al.: Volumetric analysis of functional diffusion maps (fDMs) is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant glioma. J Neurooncol. 2010;In Press.
32. Rieger J, Bahr O, Muller K, et al.: Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol. Aug 2010;99(1):49-56.
33. Rieger J, Bahr O, Ronellenfitsch MW, et al.: Bevacizumab-Induced Diffusion Restriction in PatientsWith Glioma: Tumor Progression or Surrogate Marker of Hypoxia? J Clin Oncol. Jun 28 2010.
34. Gerstner ER, Frosch MP, Batchelor TT: Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol. Feb 20 2010;28(6):e91-93.
35. Gerstner ER, Chen PJ, Wen PY, et al.: Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol. May 2010;12(5):466-472.
36. Pope WB, Kim HJ, Huo J, et al.: Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. Jul 2009;252(1):182-189.
37. Smith EA, Carlos RC, Junck LR, et al.: Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions. AJR Am J Roentgenol. Feb 2009;192(2):W45-52.
38. Weybright P, Sundgren PC, Maly P, et al.: Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol. Dec 2005;185(6):1471-1476.
39. Hattingen E, Delic O, Franz K, et al.: (1)H MRSI and progressionfree survival in patients with WHO grades II and III gliomas. Neurol Res. Jul 2010;32(6):593-602.
40. Hattingen E, Raab P, Franz K, et al.: Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology. Sep 2008;50(9):759-767.
41. Oh J, Henry RG, Pirzkall A, et al.: Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-Nacetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging. May 2004;19 (5):546-554. (Pubitemid 38619916)
42. Chen W, Cloughesy T, Kamdar N, et al.: Imaging proliferation in brain tumors with 18 F-FLT PET: comparison with 18 F-FDG. J Nucl Med. Jun 2005;46(6):945-952. (Pubitemid 43733508)
43. Chen W, Delaloye S, Silverman DH, et al.: Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18 F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. Oct 20 2007;25(30):4714-4721. (Pubitemid 350086472)
44. Potzi C, Becherer A, Marosi C, et al.: [11 C] methionine and [18 F] fluorodeoxyglucose PET in the follow-up of glioblastoma multiforme. J Neurooncol. Sep 2007;84(3):305-314.
45. Galldiks N, Ullrich R, Schroeter M, et al.: Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme. Eur J Nucl Med Mol Imaging. Jan 2010;37(1):84-92.
46. Becherer A, Karanikas G, SzaboM, et al.: Brain tumour imaging with PET: a comparison between [18 F]fluorodopa and [11 C]methionine. Eur J Nucl Med Mol Imaging. Nov 2003;30(11):1561-1567. (Pubitemid 37356125)
47. Chen W, Silverman DH, Delaloye S, et al.: 18 F-FDOPA PET imaging of brain tumors: comparison study with 18 F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. Jun 2006;47 (6):904-911. (Pubitemid 46939941)